Assay, Purity, and Impurity Profile of Phosphorothioate Oligonucleotide Therapeutics by Ion Pair-HPLC-MS.


Journal

Nucleic acid therapeutics
ISSN: 2159-3345
Titre abrégé: Nucleic Acid Ther
Pays: United States
ID NLM: 101562758

Informations de publication

Date de publication:
06 2022
Historique:
pubmed: 4 3 2022
medline: 7 6 2022
entrez: 3 3 2022
Statut: ppublish

Résumé

The relatively large molecular size, diastereoisomeric nature, and complex impurity profiles of therapeutic phosphorothioate oligonucleotides create significant analytical challenges for the quality control laboratory. To overcome the lack of selectivity inherent to traditional chromatographic approaches, an ion pair liquid chromatography-mass spectrometry (LCMS) method combining ultraviolet and mass spectrometry quantification was developed and validated for >35 different oligonucleotide drug substances and products, including several commercialized drugs. The selection of chromatographic and spectrometric conditions, data acquisition and processing, critical aspects of sample and buffer preparation and instrument maintenance, and results from method validation experiments are discussed.

Identifiants

pubmed: 35238617
doi: 10.1089/nat.2021.0056
doi:

Substances chimiques

Phosphorothioate Oligonucleotides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

206-220

Auteurs

Claus Rentel (C)

Analytical Development Quality Control, Ionis Pharmaceuticals, Carlsbad, California, USA.

Hans Gaus (H)

Analytical Development Quality Control, Ionis Pharmaceuticals, Carlsbad, California, USA.

Kym Bradley (K)

Analytical Development Quality Control, Ionis Pharmaceuticals, Carlsbad, California, USA.

Nhuy Luu (N)

Analytical Development Quality Control, Ionis Pharmaceuticals, Carlsbad, California, USA.

Kimmy Kolkey (K)

Analytical Development Quality Control, Ionis Pharmaceuticals, Carlsbad, California, USA.

Bao Mai (B)

Analytical Development Quality Control, Ionis Pharmaceuticals, Carlsbad, California, USA.

Mark Madsen (M)

Analytical Development Quality Control, Ionis Pharmaceuticals, Carlsbad, California, USA.

Megan Pearce (M)

Analytical Development Quality Control, Ionis Pharmaceuticals, Carlsbad, California, USA.

Brandon Bock (B)

Analytical Development Quality Control, Ionis Pharmaceuticals, Carlsbad, California, USA.

Daniel Capaldi (D)

Analytical Development Quality Control, Ionis Pharmaceuticals, Carlsbad, California, USA.

Articles similaires

Humans Chromatography, High Pressure Liquid Acetaminophen COVID-19 SARS-CoV-2
Humans Pisum sativum Breast Neoplasms Tandem Mass Spectrometry Plant Extracts
Humans Breast Neoplasms Female Mass Spectrometry Adipose Tissue
Humans Proteomics Paraffin Embedding Tissue Fixation Organelles

Classifications MeSH